Asphelia Pharmaceuticals Announces Fall 2008 Conference Schedule GlobeNewsWire (press release), CA - 6 hours ago Asphelia's primary focus lies in its development of therapies targeting Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), …

This entry was posted on Monday, September 22nd, 2008 at 1:26 pm and is filed under Colon, bowel disease. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.